Related Experiment Videos
Role of MBD2 in gene regulation and tumorigenesis
1Wellcome Trust Centre for Cell Biology, University of Edinburgh, Swann Building, King's Buildings, Mayfield Road, Edinburgh EH9 3JR, UK.
Abstract:
DNA methylation is an epigenetic mechanism involved in transcriptional silencing of imprinted genes, genes located on the inactive X chromosome, and a number of tumour suppressor genes in cancer. MBD (methyl-CpG-binding domain) proteins selectively bind to methylated DNA and recruit chromatin remodelling and transcriptional repressor complexes, thereby establishing a repressive chromatin state. MBD2, a member of the MBD protein family, binds to methylated promoter CpG islands (clusters of high-density CpG dinucleotides) and acts as a methylation-dependent transcriptional repressor. Previous work has demonstrated that decreased CpG island methylation in mice lacking the DNA methyltransferase DNMT1 is associated with impaired tumorigenesis when crossed on the tumour-susceptible Apc(Min/+) background. Mbd2 deficiency also dramatically reduces adenoma burden and extends life span in a gene dosage-dependent manner in this mouse model. Mbd2 is therefore essential for tumorigenesis in the murine intestine, although it is dispensable for the viability of the host animals. These findings validate MBD2 as a potential target for therapeutic intervention in colorectal cancer.
Insights
Methyl-CpG-binding domain protein 2 (MBD2) is crucial for intestinal tumor development. Inhibiting MBD2 significantly reduces tumor burden and extends lifespan in a mouse model, highlighting its therapeutic potential for colorectal cancer.
Area of Science:
- Epigenetics
- Molecular Biology
- Cancer Research
Background:
- DNA methylation is a key epigenetic regulator of gene expression, involved in silencing imprinted genes, inactive X-chromosome genes, and tumor suppressor genes.
- Methyl-CpG-binding domain (MBD) proteins bind methylated DNA, recruiting repressor complexes to establish repressive chromatin states.
- MBD2 specifically targets methylated promoter CpG islands, acting as a methylation-dependent transcriptional repressor.
Purpose of the Study:
- To investigate the role of MBD2 in intestinal tumorigenesis.
- To evaluate MBD2 as a potential therapeutic target for colorectal cancer.
Main Methods:
- Utilized a mouse model with impaired DNA methyltransferase (DNMT1) and a tumor-susceptible background (ApcMin/+) to study tumorigenesis.
- Assessed the impact of Mbd2 deficiency on adenoma burden and animal lifespan in this model.
Main Results:
- Mbd2 deficiency dramatically reduced adenoma burden in the murine intestine in a gene dosage-dependent manner.
- Mbd2 deficiency extended the lifespan of tumor-susceptible mice.
- Mbd2 was essential for intestinal tumorigenesis but dispensable for host viability.
Conclusions:
- MBD2 plays an essential role in intestinal tumor development.
- MBD2 is a validated potential therapeutic target for colorectal cancer intervention.
Related Concept Videos
Abnormal Proliferation
Master Transcription Regulators
Negative Regulator Molecules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...